Biotech has in the past been seen as a risky business vulnerable to unpredictable ups and downs. But the perception of biotech, which depends more on breakthroughs in drug technology and long-term contracts with healthcare providers than on the ups and downs of the economy, make them a potential haven in today’s unpredictable market.  CHI member company Genentech, which reports first-quarter earnings Thursday, has a long list of successful drugs in its pipeline.  Others firms reporting in the days ahead, such as Genzyme, another CHI member company, have historically had strong stock runs on sharp earnings growth.

Click here to read the full story in the Wall Street Journal.